f-Met-Leu-Phe stimulates nitric oxide production in chick embryo neurons: the role of NF-kB

Immunopharmacology and Immunotoxicology
Antonia CianciulliMaria Antonietta Panaro

Abstract

N-formyl-methionyl-leucyl-phenylalanine (fMLP) is a major chemotactic factor produced by Escherichia coli and other Gram-negative bacteria. In avian models the fMLP effects and the possible expression of FPRs have been poorly investigated. This report demonstrates that fMLP stimulation in vitro is able to elicit significant cellular responses from 10-day chick embryo nerve cells. Cell treatment with 10(-7) M fMLP at 37 degrees C induces a dramatic increase of nitric oxide (NO) production, after 24, 48, and 72 h, respectively. After 72 h of treatment with 10(-7) M fMLP the maximum nuclear translocation of the NF-kB complex protein p65 is visible, corresponding to the greatest NO production. In this context, 72 h of fMLP stimulation lead to a marked expression of the antiapoptotic protein Bcl-2, involved in cell survival. This suggests that activation of the NF-kB complex plays a protective role in chick neuronal cells treated with fMLP, confirmed by the significant neuronal cells degeneration observed after NF-kB inhibition with the specific inhibitor, TPCK. Overall, these data suggest a possible protective mechanism displayed by neurons against toxic molecules, like NO, released after cell exposure to bacterial products.

References

Apr 1, 1996·Current Opinion in Cell Biology·S Jaken
Jan 1, 1997·The Medical Clinics of North America·H AliR Snyderman
Mar 21, 1997·The Journal of Biological Chemistry·D D BrowningR D Ye
Jan 1, 1997·Advances in Second Messenger and Phosphoprotein Research·T GudermannG Schultz
Apr 15, 1999·The EMBO Journal·J Bockaert, J P Pin
Aug 31, 1999·Immunopharmacology and Immunotoxicology·M A Panaro, V Mitolo
Jan 26, 2000·Journal of Neurochemistry·M P MattsonS Camandola
Mar 11, 2000·Journal of Toxicology and Environmental Health. Part B, Critical Reviews·K M Rao
Mar 10, 2001·Journal of Neuroimmunology·M T Heneka, D L Feinstein
Apr 20, 2001·Cytokine & Growth Factor Reviews·Y LeJ M Wang
Oct 29, 2002·Trends in Immunology·Yingying LeJi Ming Wang
Jul 23, 2003·Current Drug Targets. Immune, Endocrine and Metabolic Disorders·M A PanaroV Mitolo
Jul 5, 2005·Biochimica Et Biophysica Acta·Barbara KaltschmidtChristian Kaltschmidt
Sep 28, 2005·Neurochemical Research·Mark P Mattson
Mar 7, 2006·European Journal of Pharmacology·Rita SelvaticiSusanna Spisani
May 11, 2006·Immunopharmacology and Immunotoxicology·M A PanaroV Mitolo
Jul 21, 2006·European Journal of Pharmacology·Marina Pizzi, Pierfranco Spano
Sep 26, 2006·Biochemical Pharmacology·Sylvie Mémet
Apr 28, 2007·Immunopharmacology and Immunotoxicology·M A PanaroV Mitolo
May 9, 2007·Frontiers in Bioscience : a Journal and Virtual Library·Helen J Knowles, Adrian L Harris

❮ Previous
Next ❯

Citations

Oct 4, 2012·Animal : an International Journal of Animal Bioscience·A RizzoR L Sciorsci
Mar 9, 2012·Immunopharmacology and Immunotoxicology·Concetta SaponaroMaria Antonietta Panaro

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.